Keun‐Wook Lee

Seoul National University — South Korea

Medicine · Health Sciences

55h-index15.5kcitations479works7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(173), Colorectal Cancer Treatments and Studies(87), Cancer Immunotherapy and Biomarkers(64), Gastrointestinal Tumor Research and Treatment(52), Lung Cancer Treatments and Mutations(50)

Publications477 total

Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup—Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW
Cancer Research and Treatment·2025Open Access
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
Clinical Cancer Research·2025Open Access
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up
Advances in Therapy·2025Open Access
Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Molecular Cancer Therapeutics·2025Open Access
Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer
British Journal of Cancer·2025Open Access
496 CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial
Regular and Young Investigator Award Abstracts·2025Open Access
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis
Gastric Cancer·2025· 1 citedOpen Access
VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation
2025Open Access
Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
Cardiovascular Diabetology·2025· 7 citedOpen Access
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)
Cancer Research and Treatment·2025· 2 citedOpen Access
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma
Blood Cancer Journal·2025· 2 citedOpen Access
Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial.
Journal of Clinical Oncology·2025· 1 cited
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial
Nature Communications·2025· 5 citedOpen Access
Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With<i>PIK3CA</i>Mutations and Overcoming Strategies
Anticancer Research·2025Open Access
Abstract 5990: Pertuzumab enhances the antitumor activity of T-DXd in HER2-positive gastric cancer cells
Cancer Research·2025
Survival Rates of Patients with Gastric Cancer According to Age and Sex: A Large-Scale Study Using Data from 14,739 Patients
Cancer Research and Treatment·2025Open Access
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer
Gastric Cancer·2025Open Access
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital
Cancer Research and Treatment·2025Open Access
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
Advances in Therapy·2025· 7 citedOpen Access
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial
Cancer Research and Treatment·2025· 3 citedOpen Access
page 1 of 24Next →

Frequent Co-authors

Hyun Cheol Chung(12), Yung‐Jue Bang(12), Jee Hyun Kim(12), Yoon‐Koo Kang(10), Sang Cheul Oh(10), Do‐Youn Oh(9), Narikazu Boku(7), Min‐Hee Ryu(7), Y. Choi(7), Jeeyun Lee(7), Jin Won Kim(7), Yee Chao(6), Kei Muro(6), Won Ki Kang(6), Keisho Chìn(6), Zev A. Wainberg(6), Seock‐Ah Im(6), Jeong‐Ok Lee(6), Yu Jung Kim(6), Hye Seung Lee(6)